Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2 by Ye, Lan et al.
“fgene-03-00177” — 2012/9/10 — 17:44 — page 1 — #1
ORIGINAL RESEARCH ARTICLE
published: 11 September 2012
doi: 10.3389/fgene.2012.00177
Rapamycin has a biphasic effect on insulin sensitivity
in C2C12 myotubes due to sequential disruption
of mTORC1 and mTORC2
LanYe1,2, BehzadVaramini1,2, DudleyW. Lamming3,4,5,6,7, David M. Sabatini3,4,5,6,7 and Joseph A. Baur1,2*
1 Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
2 Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
3 Whitehead Institute for Biomedical Research, Cambridge, MA, USA
4 Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA
5 Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA, USA
6 Broad Institute of Harvard, Massachusetts Institute of Technology, Cambridge, MA, USA
7 The David H. Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, MA, USA
Edited by:
S. M. Jazwinski, Tulane University,
USA
Reviewed by:
Yih-Woei Fridell, University of
Connecticut, USA
Gerald S. Shadel, Yale University
School of Medicine, USA
Michael V. Miceli, Tulane University
School of Medicine, USA
*Correspondence:
Joseph A. Baur, Institute for Diabetes,
Obesity, and Metabolism, Perelman
School of Medicine, University of
Pennsylvania, 12-114Translational
Research Center, 3400 Civic Center
Boulevard, Philadelphia, PA 19104,
USA; Department of Physiology,
Perelman School of Medicine,
University of Pennsylvania, 12-114
Translational Research Center, 3400
Civic Center Boulevard, Philadelphia,
PA 19104, USA.
e-mail: baur@mail.med.upenn.edu
Rapamycin, an inhibitor of mTOR complex 1 (mTORC1), improves insulin sensitivity in
acute studies in vitro and in vivo by disrupting a negative feedback loop mediated by S6
kinase. We ﬁnd that rapamycin has a clear biphasic effect on insulin sensitivity in C2C12
myotubes, with enhanced responsiveness during the ﬁrst hour that declines to almost
complete insulin resistance by 24–48 h.We and others have recently observed that chronic
rapamycin treatment induces insulin resistance in rodents, at least in part due to disrup-
tion of mTORC2, an mTOR-containing complex that is not acutely sensitive to the drug.
Chronic rapamycin treatment may also impair insulin action via the inhibition of mTORC1-
dependent mitochondrial biogenesis and activity, which could result in a buildup of lipid
intermediates that are known to trigger insulin resistance. We conﬁrmed that rapamycin
inhibits expression of PGC-1α, a key mitochondrial transcription factor, and acutely reduces
respiration rate in myotubes. However, rapamycin did not stimulate phosphorylation of
PKCθ, a central mediator of lipid-induced insulin resistance. Instead, we found dramatic
disruption of mTORC2, which coincided with the onset of insulin resistance. Selective inhi-
bition of mTORC1 or mTORC2 by shRNA-mediated knockdown of speciﬁc components
(Raptor and Rictor, respectively) conﬁrmed that mitochondrial effects of rapamycin are
mTORC1-dependent, whereas insulin resistance was recapitulated only by knockdown of
mTORC2. Thus, mTORC2 disruption, rather than inhibition of mitochondria, causes insulin
resistance in rapamycin-treated myotubes, and this system may serve as a useful model
to understand the effects of rapamycin on mTOR signaling in vivo.
Keywords: mTOR, mTORC1, rapamycin, mTORC2, insulin sensitivity, mitochondrial biogenesis, chronic, diabetes,
raptor, rictor, respiration
INTRODUCTION
Rapamycin is the only drug that has been unequivocally estab-
lished to robustly and reproducibly extend maximum lifespan in
mice (Harrison et al., 2009). However, very little is known about
the changes in physiology or intracellular signaling that accom-
pany this effect. Interestingly, rapamycin was tested for effects on
lifespan in part because it is proposed to mimic some of the sig-
naling events triggered by caloric restriction (CR), which extends
life in most species that have been tested (Weindruch andWalford,
1988; Baur, 2009; Cox and Mattison, 2009). Two hallmarks of
CR in rodents are improved insulin sensitivity (McKee Alderman
et al., 2010) and increased mitochondrial biogenesis (Nisoli et al.,
2005). Surprisingly, rapamycin causes insulin resistance (Houde
et al., 2010; Lamming et al., 2012) and inhibits both the production
and function of mitochondria, at least in cells (Schieke et al., 2006;
Cunningham et al., 2007; Ramanathan and Schreiber, 2009). It is
therefore clear that rapamycin does more than act as a simple
“CR mimetic,” and understanding the molecular mechanisms
involved has the potential to lead to both the development of
more effective molecules, and new insights into the underlying
processes that regulate mammalian aging.
The canonical target of rapamycin is mechanistic (formerly
mammalian) target of rapamycin complex 1 (mTORC1), a kinase
involved in nutrient sensing and the regulation of growth and
metabolism (Sabatini et al., 1994). The mTORC1 pathway is sup-
pressed by CR in a variety of mammalian tissues (e.g., Estep et al.,
2009; Lashinger et al., 2011; Shinmura et al., 2011), and interfering
with this pathway genetically in yeast results in lifespan extension
that is not additive with CR in that organism (Kaeberlein et al.,
2005). Although complete elimination of mTORC1 in mammals
causes embryonic lethality (Guertin et al., 2006), animals lacking
one of its substrates, S6K1, are long-lived and display enhanced
insulin sensitivity (Selman et al., 2009), supporting the idea that
important features of CR may be mediated by suppression of this
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pathway. We have recently described a strain of mice with mildly
impaired mTORC1 signaling that are also long-lived (Lamming
et al., 2012). However, these mice lack the enhanced insulin sen-
sitivity that is conferred by total S6K1 ablation, suggesting that
the two effects are separable. Consistent with this, we and oth-
ers have reported that rodents treated with rapamycin are overtly
insulin resistant (Houde et al., 2010; Lamming et al., 2012), despite
the longer lifespan of rapamycin-treated mice (Chen et al., 2009;
Harrison et al., 2009).
We have shown that rapamycin-induced insulin resistance in
mice is at least partially due to disruption of mTORC2, a second
mTOR-containing complex that phosphorylates several substrates,
includingAKT at serine 473 as part of the insulin signaling cascade
(Figure 1; Lamming et al., 2012). mTORC2 is not acutely sensitive
to rapamycin, but was shown to be disrupted in some, but not all,
cultured cell lines after continuous exposure to the drug (Sarbassov
et al., 2006). In addition, loss of AKTphosphorylation at serine 473
after prolonged rapamycin treatment has been observed in vivo,
consistent with our biochemical demonstration thatmTORC2 can
be disrupted in intact tissues in mice.
FIGURE 1 | Interdependence of signaling through the insulin receptor
and mTOR. mTORC1, the canonical target of rapamycin, is downstream of
the insulin signaling cascade and mediates negative feedback through
S6K1. mTORC2 is an AKT kinase that is not sensitive to acute rapamycin
treatment (∼1 h), but can be inhibited by chronic exposure (∼24 h).
Phosphorylation of AKT by PDK1 and mTORC2 occurs at discrete sites
(threonine 308 and serine 473, respectively). mTORC1 promotes
mitochondrial biogenesis, although the relevance of this observation to its
effects on insulin sensitivity has not been established. Solid lines indicate
direct effects, whereas dashed lines indicate intermediate steps, or in the
case of rapamycin inhibiting mTORC2, the requirement for chronic
exposure.
A possibility that has not been adequately addressed to date
is that decreased abundance or function of mitochondria could
contribute to the detrimental effects of rapamycin on metabolism.
In stark contrast to CR (Nisoli et al., 2005), rapamycin has been
shown to suppress mitochondrial biogenesis (Cunningham et al.,
2007), and to acutely decrease mitochondrial respiration in cul-
tured cells (Schieke et al., 2006; Ramanathan and Schreiber, 2009).
A large body of evidence supports the contention that insufﬁcient
mitochondrial capacity in skeletal muscle can trigger a buildup of
lipid-derived molecules, including diacylglycerols and ceramides,
that subsequently trigger activation of PKCθ, inhibitory serine
phosphorylation of IRS1, and insulin resistance (Morino et al.,
2006; Erion and Shulman, 2010).
In C2C12 myotubes, we have observed a clear biphasic effect
of rapamycin on insulin sensitivity. We show that an early (∼1 h)
improvement in insulin responsiveness correlates to the acute loss
of signaling through S6K1, consistent with disruption of the neg-
ative feedback loop driving inhibitory phosphorylation of IRS1
(Figure 1; Um et al., 2004). At later time points (>24 h), however,
we ﬁnd that myotubes become refractory to the effects of insulin.
We provide biochemical and genetic evidence to show that disrup-
tion of mTORC2, rather than mitochondrial dysfunction, plays
the dominant role in rapamycin-induced insulin resistance. These
studies expand our understanding of the molecular consequences
of rapamycin exposure, and how these changes inﬂuence insulin
sensitivity in a cell culture model of skeletal muscle.
MATERIALS AND METHODS
MATERIALS
Antibodies to phospho-AKT S473 (9271), phospho-AKT T308
(9275), AKT (9272), phospho-S6 ribosomal protein (2215), S6
ribosomal protein (2217), mTOR (2972), Raptor (2280), Rictor
(2140), phospho-PKC theta T538 (9377), and VDAC (4866) were
from Cell Signaling Technology. The phospho-IRS1 S307 (07-
247) antibody was from Upstate and IRS1 (05-1085) and GAPDH
(JC1641540) antibodies were from Millipore. OXPHOS cocktail
(MS604/D1848) was from MitoSciences. Protease and phos-
phatase inhibitor cocktail tablets were from Roche (11836153001
and 04906845001, respectively). Rapamycin was purchased from
Calbiochem (553210). Torin1 was a gift from the lab of Nathanael
Gray. Triglyceride reagent was from Stanbio Laboratory. DMEM,
fetal bovine serum (FBS), horse serum, insulin, protein A agarose,
and Trizol were obtained from Invitrogen. Other chemicals were
purchased from Sigma unless noted.
CELL CULTURE
C2C12 mouse myoblasts were maintained in DMEM supple-
mented with 10% FBS and antibiotics (Pen/Strep). When cells
reached conﬂuence, the medium was switched to DMEM with 2%
horse serum. Cells were refreshed with differentiation medium
every other day. By day 4, C2C12s were fused into myotubes.
C2C12 myotubes were then treated with 500 nM rapamycin for
the indicated times. Torin1 treatment was at 250 nM for 4 h.
Palmitate-containing media were prepared by conjugating palmi-
tate with FFA-free bovine serum albumin as described by Chavez
et al. (2005). Brieﬂy, palmitate was dissolved in ethanol (75 mM),
diluted 1:25 in DMEM containing 2% BSA, sonicated brieﬂy, and
Frontiers in Genetics | Genetics of Aging September 2012 | Volume 3 | Article 177 | 2
“fgene-03-00177” — 2012/9/10 — 17:44 — page 3 — #3
Ye et al. Rapamycin disrupts mTORC2 in myotubes
incubated at 55◦C for 10 min. The complexed palmitate was then
diluted to a ﬁnal concentration of 0.5 mM in DMEM contain-
ing 2% BSA, cooled at RT, ﬁltered and administrated to C2C12
myotubes for 16 h.
OXYGEN CONSUMPTION RATE MEASUREMENT
C2C12 myoblasts were seeded at 40,000 cells per well in 24-well
XF plates. Myoblasts were treatedwith rapamycin for the indicated
times, or alternatively, myotubes were generated by replacing the
medium with differentiation medium when cells reached conﬂu-
ence. After an 4 days of differentiation,myotubes were treatedwith
rapamycin for the indicated times. The cells were refreshed with
non-buffered pH 7.4 medium (25 mM glucose) and incubated for
1 h in a non-CO2 incubator, as recommended by Seahorse Bio-
sciences. A Seahorse XF24 Analyzer (Seahorse Biosciences) was
then used to measure the oxygen consumption rate. Each cycle
included 4 min of mixing, a 2-min wait, and then measurement
over 2 min. One micromolar oligomycin was used to inhibit ATP
synthase. Next, 300 nM FCCP was added to stimulate uncoupled
respiration. Immediately after measurement, the protein concen-
tration was measured by bicinchoninic acid (BCA) assay (Pierce
Biotechnology).
WESTERN BLOTTING
Cells were rinsed with PBS and lysed in cold RIPA buffer sup-
plemented with phosphatase inhibitor and protease inhibitor
cocktail tablets. Cell lysates were incubated on ice for 10 min,
sonicated on ice for 30 s, and centrifuged at 12,800 rpm for
15 min at 4◦C. Protein concentration was determined by BCA
assay (Pierce Biotechnology). Twenty microgram proteins were
separated by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) on 8–16% gradient or 7.5% resolving
gels. Quantiﬁcation was performed by densitometry using ImageJ
software, and loading was veriﬁed by blotting for GAPDH.
IMMUNOPRECIPITATIONS
C2C12 myotubes were lysed in cold 0.3% CHAPS lysis buffer
[40 mM Hepes (pH 7.5), 120 mM NaCl, 1 mM EDTA, 0.3%
CHAPS, 10 mM pyrophosphate, 10 mM β-glycerophosphate,
50mMNaF,0.5mMorthovanadate, andprotease inhibitors]. Cells
lysates were incubated at 4◦C for 15 min and then centrifuged at
16,000 rpm for 15 min at 4◦C to remove insoluble material. Pro-
tein A agarose beads were added to the supernatant and incubated
with rotation for 1 h. Next, the beads were centrifuged out of the
lysates and mTOR or Rictor antibodies were added to the cleared
lysates, which were rotated overnight at 4◦C. Protein A agarose
beads were added to the supernatant and incubated at 4◦C for
an additional hour. Immunoprecipitated complexes with protein
A agarose beads were washed in 0.3% CHAPS lysis buffer three
times, boiled in SDS-sample buffer, separated by SDS-PAGE (7.5%
gels), and analyzed by immunoblotting. This method is adapted
from that described by Sarbassov et al. (2006).
QUANTITATIVE REAL TIME RT-PCR ASSAY
Total RNA was extracted from the sample using TRIzol reagent.
The concentration and purity of RNA were determined by
absorbance at 260/280 nm. One microgram of total RNA was
reverse transcribed using a high-capacity cDNA reverse tran-
scription kit (Applied Biosystems) according to the manufac-
turer’s instructions. The cDNA was subjected to real time PCR
using SYBR Q-PCR master mix (Applied Biosystems). Primer
sequences used to produce gene-speciﬁc amplicons are as fol-
lows: PGC-1α: forward: ACTATGAATCAAGCCACTACAGAC;
reverse: TTCATCCCTCTTGAGCCTTTCG, GAPDH: forward:
GGTGAAGGTCGGAGTCAACGGA; reverse: GAGGGATCTCG-
CTCCTGGAAGA, TFAM: forward: AAGACCTCGTTCAGCATA-
TAACATT; reverse: TTTTCCAAGCCTCATTTACAAGC,A typical
reaction contained 250 nM of forward and reverse primer, 1 μl
cDNA and the ﬁnal reaction volume was 20 μl. The reaction
was initiated by preheating at 50
◦
C for 2 min, followed by
95
◦
C for 10 min. Subsequently, 40 ampliﬁcation cycles were
carried out with 15 s denaturation at 95
◦
C and 30 s anneal-
ing and extension at 60
◦
C. Gene expression was normalized to
GAPDH.
mtDNA DETERMINATION
Brieﬂy, cell pellets were digested in with 15 μl proteinase K
(10 mg/ml) in a 500 μl total volume of proteinase K buffer
(100 mM Tris-HCl pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM
NaCl) overnight at 55◦C. 170 μl of 5 M NaCl was added and sam-
ples were mixed for 1 min and then centrifuged at max speed for
15 min at 4◦C. Supernatants were collected and 1 ml ethanol was
added, after which the tubes were inverted several times. Sam-
ples were centrifuged at max speed for 15 min at 4◦C, after which
ethanol supernatant was aspirated and DNA pellet was washed in
500 μl of 70% ethanol. Samples were centrifuged for 5 min, max
speed at 4◦C, ethanol supernatant was removed, the DNA pellet
was air dried and resuspended in 50 μl of TE. Primer sequences
used to producemitochondrial and nuclear speciﬁcDNAproducts
for quantiﬁcation of mtDNA/nuclear DNA ratios are as fol-
lows: MT-CO1: forward: TGCTAGCCGCAGGCATTAC; reverse:
GGGTGCCCAAAGAATCAGAAC, Ndufv1: forward: CTTCCC-
CACTGGCCTCAAG; reverse: CCAAAACCCAGTGATCCAGC.
KNOCKDOWN OF RICTOR AND RAPTOR WITH LENTIVIRUS
293T cells were from ATCC and were seeded onto 10 cm diameter
dishes with DMEM (supplemented with 10% FBS and penicillin–
streptomycin) and incubated overnight. When the cells became
70% conﬂuent, they were refreshed the cells with antibiotic-free
DMEM. Next, the Rictor shRNA, Raptor shRNA, and control
GFP shRNA plasmids (Guertin et al., 2009; Thoreen et al., 2009),
together with helper vectors pCMV-dR8.2dvpr and pCMV-VSVG,
were cotransfected into 293T cells using Fugene reagent. Media
containing lentivirus were harvested after 48 h and passed through
a 0.4 μM ﬁlter. C2C12 myoblasts were infected with lentivirus-
containing media for 24 h and selected with 2 μg/ml puromycin.
The cell lysates were harvested at appropriate time points and
analyzed by immunoblotting.
MEASUREMENT OF TRIGLYCERIDES
C2C12 myotubes were lysed in PBS containing 1% Nonidet P-40.
Triglycerides were determined by triglyceride reagent according
to manufacture’s instructions (Stanbio Laboratory). Intracellular
triglycerides were normalized to total protein content.
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FIGURE 2 | Effects of rapamycin, AICAR, and resveratrol on
palmitate-induced insulin resistance. (A) Palmitate renders C2C12
myotubes refractory to insulin stimulation, as reﬂected by downstream
phosphorylation of AKT. One hour of pre-treatment with resveratrol
mildly increases insulin resistance, consistent with previous reports
of acute inhibition of insulin signaling (Zhang, 2006), whereas the AMPK
activator AICAR is without effect, and rapamycin slightly improves insulin
signaling, likely due to disruption of negative feedback through S6K1
(Um et al., 2004). After 48 h of pre-treatment, AICAR rescues insulin
signaling, while rapamycin renders myotubes almost completely resistant.
The effects of AICAR and rapamycin on insulin signaling were each veriﬁed
in at least three independent experiments and representative blots are
shown. (B) Quantiﬁcation of the effects of short- (1 h) and long-term
(48 h) exposure to rapamycin on the insulin-stimulated phosphorylation
of AKT in palmitate-treated C2C12 myotubes. *p < 0.05. Error bars
show SEM.
STATISTICAL ANALYSIS
Densitometry was performed using ImageJ software (NIH,
Bethesda, MD) and band intensities were normalized to GAPDH,
unless otherwise indicated. Signiﬁcance was tested using the two-
tailed unpaired Student’s t-test in Microsoft Excel (Microsoft,
Seattle, Washington) or a one-sample t-test to test whether ratios
of phosphorylatedAkt differed signiﬁcantly from the control value
(set to one) in Figures 2 and 6. * denotes p < 0.05 compared to
control unless otherwise indicated.
RESULTS
We initially chose to explore the effects of rapamycin in differ-
entiated C2C12 myotubes cultured in the presence of palmitate
because it is known that insulin sensitivity in this system is
decreased by the accumulation of lipid intermediates, such as
diacylglycerols and ceramides, and that enhancing mitochondrial
fatty acid oxidation is sufﬁcient to improve insulin sensitivity (Coll
et al., 2010). Therefore, we expected that any major inﬂuence
of rapamycin on mitochondrial function would be reﬂected as
a change in insulin signaling to AKT.
We found that pre-treatment of C2C12 myotubes with
rapamycin for 1 h caused a small, but reproducible improve-
ment in insulin sensitivity, likely due to the loss of negative
feedback through S6K1, a substrate of the canonical rapamycin
target, mTORC1 (Figure 2). Over four independent experiments,
the average effect of short-term rapamycin was an approxi-
mately 50% increase in the pAkt:Akt ratio following insulin
stimulation, p = 0.02. Interestingly, when the rapamycin pre-
treatment was extended to 48 h, the myotubes became almost
completely unresponsive to insulin stimulation, consistent either
with further antagonism of lipid-induced insulin resistance via
inhibition of mitochondria, or with disruption of mTORC2. Over
four independent experiments, the average effect was a 67%
decrease in the pAkt:Akt ratio, p < 0.001. AICAR, an AMPK
activator that promotes respiration and mitochondrial biogen-
esis (Ojuka, 2004), had the opposite effect, improving insulin
sensitivity at the 48 h time point, whereas a second compound
known to promote mitochondrial biogenesis, resveratrol, had
no effect.
To test whether rapamycin was sufﬁcient to suppress mito-
chondrial function, we measured respiration rates in treated
or untreated myotubes using a Seahorse XF24 Flux Analyzer.
As shown in Figure 3, pre-treatment with rapamycin caused a
signiﬁcant reduction in respiration rates under basal, oligomycin-
inhibited (reﬂecting proton leak), and uncoupled conditions (all
in the presence of 25 mM glucose). To test whether rapamycin
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FIGURE 3 | Rapamycin suppresses oxygen consumption in myotubes.
Oxygen consumption was measured using a Seahorse XF24 Flux Analyzer.
C2C12 myoblasts were differentiated on Seahorse plates and pre-treated
with rapamycin or vehicle (DMSO) for the indicated times. Glucose was
maintained at 25 mM throughout the experiment. Acute addition of
palmitate (0.5 mM ﬁnal concentration, in complex with BSA) had only a
minor effect on total oxygen consumption, which was reversed with
etomoxir (50 μM), an inhibitor of carnitine palmitoyl transferase 1.
Oligomycin was then added to inhibit ATP synthase and determine the rate
of proton leak across the mitochondrial membrane. Finally, FCCP was
added to uncouple mitochondria and measure maximal respiration rate.
Decreased respiration in rapamycin-treated cells was veriﬁed in three
independent experiments, consistent with previous reports (Schieke et al.,
2006; Ramanathan and Schreiber, 2009). The length of rapamycin
pre-treatment (1 h vs. 24 h) had a signiﬁcant effect on respiration rate under
basal, but not uncoupled conditions. *p < 0.05. Error bars show SEM.
might have changed the substrate preference of the mitochon-
dria, we also added palmitate to the media. However, the addition
of a fatty acid substrate did not restore respiration rates in the
rapamycin-treated cells, and had only a minor effect on oxygen
consumption, which was reversed upon addition of the carnitine
palmitoyl transferase 1 (CPT-1) inhibitor etomoxir. Intriguingly,
a signiﬁcant reduction in oxygen consumption occurred after 1 h
of pre-treatment, suggesting that it was largely due to changes in
ﬂux through the existing mitochondria, rather than to a reduction
in the rate of mitochondrial biogenesis.
Next, we examined factors related to mitochondrial biogen-
esis and lipid-induced insulin resistance in rapamycin-treated
myotubes. Although we conﬁrmed the previously reported sup-
pression of mitochondrial transcription factors (PGC-1α and
TFAM; Figure 4A; Cunningham et al., 2007) and were able to
show a small increase in triglyceride accumulation (Figure 4B), we
did not detect any signiﬁcant effect of rapamycin on mitochon-
drial DNA content or the levels of various mitochondrial proteins
over the time course of this experiment (Figures 4C,D). Lipid-
induced insulin resistance is typically associated with increased
phosphorylation of atypical PKC isoforms and inhibitory (ser-
ine) phosphorylation of IRS1. Serine phosphorylation of IRS1
was not enhanced. In fact, IRS1 phosphorylation was diminished
in the presence of rapamycin at all time points studied, likely
reﬂecting the inhibition of S6K1. Phosphorylated (active) PKCθ
(also called PRKCQ), was clearly higher in the presence of palmi-
tate, and appeared to be incrementally increased by rapamycin.
However, there was no induction of PKCθ phosphorylation by
rapamycin in the absence of palmitate, yet the myotubes still
became insulin resistant (Figure 4D). Together, these observa-
tions strongly suggested that mitochondrial dysfunction, leading
to lipid-induced insulin resistance is not the major mechanism
accounting for reduced insulin sensitivity in rapamycin-treated
myotubes.
Next, we assessed the integrity of the mTORC2 complex. We
found that 24 h, but not 1 h, of rapamycin exposure is sufﬁcient
to almost completely disrupt mTORC2 in C2C12 myotubes, as
assessed by immunoprecipitation of either Rictor (an mTORC2-
speciﬁc component) or the mTOR catalytic subunit (Figure 5).
These results could account for the loss of AKT phosphorylation
at serine 473, which appears to be required for subsequent phos-
phorylation by PDK1 at threonine 308 in many cases (Sarbassov
et al., 2005). However, it has been reported that loss of mTORC2
in MEFs or in skeletal muscle selectively impairs serine 473 phos-
phorylation, with unchanged or even enhanced phosphorylation
of threonine 308 (Jacinto et al., 2006; Bentzinger et al., 2008). We
therefore wondered whether the loss of threonine 308 phosphory-
lation in our myotubes was indicative of a second mechanism
contributing to insulin resistance, or simply a consequence of
mTORC2 loss.
To conﬁrm the speciﬁcity of rapamycin’s effects, we used
shRNAs to selectively ablate either mTORC1 or mTORC2 by tar-
geting the complex-speciﬁc components Raptor or Rictor, respec-
tively (Guertin et al., 2009; Thoreen et al., 2009). As expected,
Raptor knockdown recapitulated both the improved insulin sen-
sitivity due to loss of negative feedback through S6K1, and
the inhibition of respiration seen in rapamycin-treated cells
(Figure 6). On the other hand, Rictor knockdown signiﬁcantly
diminishedAKTphosphorylation at serine 473 aswell as threonine
308, conﬁrming that this site is sensitive to mTORC2 inhibition in
C2C12 myotubes (Figure 6A). Torin1, a direct inhibitor of both
mTORC1 and mTORC2 (Thoreen et al., 2009), also blocked AKT
phosphorylation at both threonine 308 and serine 473 (Figure 6B),
although it should be noted that inhibition of upstream sig-
naling through PI3K may have contributed to the Torin1 result
(Liu et al., 2012). Taken together, our results demonstrate that
rapamycin-induced insulin resistance in this system is due primar-
ily to mTORC2 disruption, rather than to mitochondrial effects of
the drug.
DISCUSSION
We have shown that both the short-term improvement in insulin
sensitivity and the longer-term loss of insulin sensitivity that are
caused by rapamycin in vivo can be mimicked in C2C12 myotubes,
and that this system can be used to explore the underlying
molecular mechanisms.
We chose C2C12 myotubes as a cell culture model to test the
contribution of mitochondria to rapamycin-induced insulin resis-
tance for a number of reasons. First, insulin resistance is readily
induced in this model with palmitate, and can be ameliorated
using a small molecule that enhances mitochondrial fatty acid
oxidation (Coll et al., 2010). Second, the ability of rapamycin to
inhibit mitochondrial biogenesis was ﬁrst demonstrated in C2C12
myotubes, and has only been thoroughly characterized in this
system (Cunningham et al., 2007). Third, we have shown that
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FIGURE 4 | Rapamycin inhibits mitochondrial transcription factors,
but has no major effect on mitochondrial protein levels or PKCθ
phosphorylation. (A) Forty-eight hours of rapamycin treatment decreases
expression of PGC-1α andTFAM, two of the major transcription factors
involved in mitochondrial biogenesis, as well as the level of MT-CO1, an
mtDNA-encoded transcript. (B) Rapamycin mildly increases intracellular
triglyceride levels in myotubes. The result show is representative of three
separate experiments. (C) Forty-eight hours of rapamycin treatment has no
effect on mitochondrial DNA copy number, as reﬂected by the ratio between
MT-CO1 (mitochondrial DNA-encoded) and Ndufv1 (nuclear-encoded)
DNA. (D) Preincubation of myotubes with rapamycin for 24 h or more
induces insulin resistance irrespective of the presence of palmitate.
Rapamycin-induced insulin resistance is not associated with major increases
in serine phosphorylation of IRS1 or phosphorylation of PKCθ, two hallmarks
of insulin resistance caused by insufﬁcient oxidation of fatty acids. Moreover,
there is no change in the expression of several proteins involved in electron
transport complexes or in the level of VDAC, a structural protein in the
mitochondria. *p < 0.05. Error bars show SEM.
FIGURE 5 | Rapamycin disrupts mTORC2 in myotubes. mTORC2 was
immunoprecipitated from myotubes that were pre-treated with vehicle,
rapamycin for 1 h, or rapamycin for 24 h, using antibodies to Rictor (A) or
mTOR (B). The integrity of the complex was assessed by blotting for the
opposite subunit. In each case, mTORC2 formation was disrupted at 24 h
despite only minor changes in total protein levels. The mTORC1 subunit
Raptor was also absent from mTOR immunoprecipitates at either
1 or 24 h.
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FIGURE 6 | Knockdown of mTORC1 reduces oxygen consumption
while knockdown of mTORC2 causes insulin resistance in myotubes.
(A) C2C12 myoblasts were infected with shRNAs targeting Raptor (mTORC1)
or Rictor (mTORC2) and differentiated. Cells were harvested with or without
insulin stimulation and probed for phosphorylation of AKT at threonine 308
and serine 473. Results shown are representative of three independent
experiments. (B) Quantiﬁcation of changes in the ratio of phosphorylated to
total AKT following knockdown of mTOR complex subunits. (C)Torin1, an
inhibitor of both mTORC1 and mTORC2 is sufﬁcient to block phosphorylation
of AKT at both sites, although direct inhibition of upstream phosphoinositide
3-kinase may contribute to this effect (Liu et al., 2012). C2C12 myoblasts
were differentiated and treated with Torin1 (250 nM for 4 h) or rapamycin
(500 nM for 24 h) (D) Knockdown of Raptor partially suppresses oxygen
consumption in the absence of rapamycin. C2C12 myoblasts were
pre-treated with rapamycin or vehicle (DMSO) for 24 h and then analyzed
on the Seahorse XF24 Flux Analyzer in unbuffered DMEM (25 mM glucose)
in the presence of rapamycin or DMSO, as indicated. Oligomycin was
added to inhibit ATP synthase in order to determine the rate of proton
leak across the mitochondrial membrane, and FCCP was subsequently
added to uncouple mitochondria and measure maximal respiration rate.
#p < 0.05 one-tailed; *p < 0.05 two-tailed; ns, not signiﬁcant. Error bars
show SEM.
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AKT phosphorylation is robustly reduced in vivo in skeletal mus-
cle by rapamycin treatment (Lamming et al., 2012). The effect of
chronic rapamycin onmTORC2 complex formationwas originally
explored in a series of immortalized and tumor cell lines, many
of which proved refractory to the drug for reasons that remain
unclear (Sarbassov et al., 2006). Herein, we show that this dif-
ferentiated, post-mitotic cell type remains sensitive to mTORC2
disruption by rapamycin.
Rapamycin has previously been established to inhibit both
mitochondrial biogenesis (Cunningham et al., 2007) and oxidative
phosphorylation by existing mitochondria (Schieke et al., 2006;
Ramanathan and Schreiber, 2009), raising the possibility that a
buildup of lipid intermediates due to insufﬁcient fatty acid oxi-
dation might trigger insulin resistance through the PKCθ to IRS1
signaling cascade in rapamycin-treated cells (Morino et al., 2006).
Indeed, palmitate-induced insulin resistance correlated with a
pronounced induction of PKCθ phosphorylation that was mildly
augmented by rapamycin. Rapamycin also caused a decrease in the
expression of keymitochondrial transcription factors and an acute
suppression of respiration in our differentiated C2C12 myotubes.
However, we found that mTORC2 disruption, rather than mito-
chondrial dysfunction, was the major cause of insulin resistance
after chronic rapamycin exposure.
Nevertheless, the incremental increase in triglyceride buildup,
increase in PKCθ phosphorylation in palmitate-treated cells, and
reduced expressionof PGC-1α andTFAM,hint thatmitochondrial
effects might exacerbate the insulin resistance caused by mTORC2
disruption, particularly in longer-term experiments in vivo. The
lack of an appreciable decrease in mitochondrial proteins over
the course of 64 h is perhaps not surprising, since many have
half lives on the order of 1–3 weeks (Menzies and Gold, 1971).
However, long-term changes in the expression of PGC-1α and
TFAM are sufﬁcient to drive changes in total mitochondrial con-
tent (Wu et al., 1999) and the abundance and transcription of
mtDNA, respectively (Larsson et al., 1998). Moreover, evidence
from human studies suggest that a 38% decrease in mitochon-
drial density may be enough to predispose humans to diabetes
(Morino et al., 2006). Therefore, it will be extremely interesting to
examine the consequences of long-term rapamycin treatment on
mitochondrial function in vivo.
Interestingly, a third potential mechanism by which rapamycin
could cause insulin resistance in skeletal muscle was recently
described by Blattler et al. (2012), who showed that 2 weeks of
rapamycin treatment decreased expression of YY1 target genes,
including upstream components of the insulin signaling cascade.
Thismechanism is unlikely to be important in ourC2C12myotube
model because YY1 interacts with mTORC1, and our shRNA
experiments implicate mTORC2 inhibition as the cause of insulin
resistance. In addition, the time frame for our experiments is
much shorter, allowing less time for changes in protein level. For
example, the expression of IRS1, one of the YY1 targets stud-
ied by Blattler et al. (2012), is unchanged in myotubes after 64 h
of rapamycin treatment (Figure 4D). However, this mechanism
may play a role in the longer-term effects of rapamycin on insulin
sensitivity in skeletal muscle in vivo.
It is also intriguing to speculate that rapamycinmay have effects
that are independent from the mTOR complexes, in cells and
in vivo. Rapamycin binds directly to FKBP12 and FKBP12.6, and
inhibits mTORC1 via a drug-induced interaction (Sabatini et al.,
1994). FKBP12 proteins have mTORC1-independent functions
in the regulation of calcium channels that can lead to cardiac
(Xin et al., 2002) and neuronal (Gant et al., 2011) phenotypes,
and FKBP12.6 null mice exhibit strain-dependent alterations in
insulin secretion (Noguchi et al., 2008; Chen et al., 2010). There-
fore, the in vivo consequences of rapamycin treatmentmay include
effects that go beyond the canonical inhibition of mTORC1 and
the disruption of mTORC2.
Rapamycin is the only drug that has been proven to extend the
maximum lifespan of a mammalian species in a rigorous, multi-
center trial using lean, healthy animals that are not predisposed
to any speciﬁc disease (Harrison et al., 2009). In contrast, many
othermolecules that improvemeasures of health andproduce ben-
eﬁts that are thought to be consistent with longevity have failed
to achieve an extension of maximum lifespan (e.g., Pearson et al.,
2008; Miller et al., 2010; Smith et al., 2010). Although rapamycin
is in clinical use, its detrimental side effects on lung health, serum
lipid proﬁles, and immune function, as well as a possible increased
risk of diabetes, are likely to preclude its use in healthy humans
(Teutonico et al., 2005; Larsen et al., 2006; Stallone et al., 2009).
Therefore, there is an urgent need and opportunity to understand
how rapamycin works at the molecular level. The present results
improve our understanding of how rapamycin inﬂuences mito-
chondria and insulin signaling, and lay the groundwork for future
studies in cells and in vivo.
ACKNOWLEDGMENTS
We would like to thank all the members of the Baur and Saba-
tini labs for help with protocols, reagents and advice. We thank
Nathanael Gray for generously providing Torin1. This project was
funded in part by a Research Grant from AFAR and a Bingham
Trust Pilot Award from Penn’s Institute on Aging to Joseph A.
Baur. Lan Ye is supported by a Postdoctoral Fellowship from the
American Heart Association, 7600031, and Dudley W. Lamming
was supported by a Ruth L. Kirschstein National Research Ser-
vice Award, 1F32AG032833-01A1 and is a Charles A. King Trust
Postdoctoral Fellow. Access to equipment was provided by Penn’s
DERC (P30DK19525). David M. Sabatini is an Investigator of the
Howard Hughes Medical Institute.
REFERENCES
Baur, J. A. (2009). “Metabolic effects of
caloric restriction,” in Encyclopedia of
Life Sciences (Chichester: John Wiley
& Sons, Ltd).
Bentzinger,C. F., Romanino,K.,Cloetta,
D., Lin, S., Mascarenhas, J. B., Oliv-
eri, F., Xia, J., Casanova, E., Costa,
C. F., Brink, M., Zorzato, F., Hall, M.
N., and Rüegg, M. A. (2008). Skele-
tal muscle-speciﬁc ablation of raptor,
but not of rictor, causes metabolic
changes and results in muscle dystro-
phy. Cell Metab. 8, 411–424.
Blattler, S. M., Cunningham, J. T.,
Verdeguer, F., Chim, H., Haas, W.,
Liu, H., Romanino, K., Ruegg,
M. A., Gygi, S. P., Shi, Y., and
Puigserver, P. (2012). Yin Yang 1
deﬁciency in skeletal muscle protects
against rapamycin-induced diabetic-
like symptoms through activation of
insulin/IGF signaling. Cell Metab. 15,
505–517.
Chavez, J. A., Holland, W. L., Bar, J.,
Sandhoff, K., and Summers, S. A.
(2005). Acid ceramidase overexpres-
sion prevents the inhibitory effects of
saturated fatty acids on insulin signal-
ing. J. Biol. Chem. 280, 20148–20153.
Chen, C., Liu, Y., and Zheng, P. (2009).
mTOR regulation and therapeutic
Frontiers in Genetics | Genetics of Aging September 2012 | Volume 3 | Article 177 | 8
“fgene-03-00177” — 2012/9/10 — 17:44 — page 9 — #9
Ye et al. Rapamycin disrupts mTORC2 in myotubes
rejuvenation of aging hematopoietic
stem cells. Sci. Signal. 2, ra75.
Chen, Z., Li, Z., Wei, B., Yin, W.,
Xu, T., Kotlikoff, M. I., and Ji,
G. (2010). FKBP12.6-knockout mice
display hyperinsulinemia and resis-
tance to high-fat diet-induced hyper-
glycemia. FASEB J. 24, 357–363.
Coll, T., Alvarez-Guardia, D., Barroso,
E., Gomez-Foix, A. M., Palomer,
X., Laguna, J. C., and Vazquez-
Carrera, M. (2010). Activation of
peroxisome proliferator-activated
receptor-{delta} by GW501516 pre-
vents fatty acid-induced nuclear
factor-{kappa}B activation and
insulin resistance in skeletal
muscle cells. Endocrinology 151,
1560–1569.
Cox, L. S., and Mattison, J. A. (2009).
Increasing longevity through caloric
restriction or rapamycin feeding in
mammals: common mechanisms for
common outcomes? Aging Cell 8,
607–613.
Cunningham, J. T., Rodgers, J. T., Arlow,
D. H., Vazquez, F., Mootha, V. K., and
Puigserver, P. (2007). mTOR con-
trols mitochondrial oxidative func-
tion through a YY1-PGC-1alpha
transcriptional complex. Nature 450,
736–740.
Erion, D. M., and Shulman, G.
I. (2010). Diacylglycerol-mediated
insulin resistance. Nat. Med. 16,
400–402.
Estep, P. W. III, Warner, J. B., and
Bulyk,M. L. (2009). Short-term calo-
rie restriction in male mice feminizes
gene expression and alters key regu-
lators of conserved aging regulatory
pathways. PLoS ONE 4, e5242. doi:
10.1371/journal.pone.0005242
Gant, J. C., Chen, K. C., Nor-
ris, C. M., Kadish, I., Thibault,
O., Blalock, E. M., Porter, N. M.,
and Landﬁeld, P. W. (2011). Dis-
rupting function of FK506-binding
protein 1b/12.6 induces the Ca2+-
dysregulation aging phenotype in
hippocampal neurons. J.Neurosci. 31,
1693–1703.
Guertin, D. A., Stevens, D. M., Saitoh,
M., Kinkel, S., Crosby, K., Sheen, J.
H., Mullholland, D. J., Magnuson,
M. A., Wu, H., and Sabatini, D. M.
(2009). mTOR complex 2 is required
for the development of prostate can-
cer induced by Pten loss in mice.
Cancer Cell 15, 148–159.
Guertin, D. A., Stevens, D. M., Thoreen,
C. C., Burds, A. A., Kalaany, N. Y.,
Moffat, J., Brown, M., Fitzgerald,
K. J., and Sabatini, D. M. (2006).
Ablation inmice of themTORCcom-
ponents raptor, rictor, or mLST8
reveals that mTORC2 is required
for signaling to Akt-FOXO and
PKCalpha, but not S6K1. Dev. Cell 11,
859–871.
Harrison, D. E., Strong, R., Sharp,
Z. D., Nelson, J. F., Astle, C. M.,
Flurkey, K., Nadon, N. L., Wilkin-
son, J. E., Frenkel, K., Carter, C. S.,
Pahor, M., Javors, M. A., Fernan-
dez, E., and Miller, R. A. (2009).
Rapamycin fed late in life extends
lifespan in genetically heterogeneous
mice. Nature 460, 392–395.
Houde, V. P., Brule, S., Festuccia,
W. T., Blanchard, P. G., Bellmann,
K., Deshaies, Y., and Marette, A.
(2010). Chronic rapamycin treat-
ment causes glucose intolerance and
hyperlipidemia by upregulating hep-
atic gluconeogenesis and impairing
lipid deposition in adipose tissue.
Diabetes Metab. Res. Rev. 59, 1338–
1348.
Jacinto, E., Facchinetti, V., Liu, D.,
Soto, N., Wei, S., Jung, S. Y., Huang,
Q., Qin, J., and Su, B. (2006).
SIN1/MIP1 maintains rictor-mTOR
complex integrity and regulates Akt
phosphorylation and substrate speci-
ﬁcity. Cell 127, 125–137.
Kaeberlein, M., Powers, R. W. III, Stef-
fen, K. K., Westman, E. A., Hu, D.,
Dang, N., Kerr, E. O., Kirkland, K.
T., Fields, S., and Kennedy, B. K.
(2005). Regulation of yeast replica-
tive life span by TOR and Sch9 in
response to nutrients. Science 310,
1193–1196.
Lamming, D. W., Ye, L., Katajisto, P.,
Goncalves,M. D., Saitoh,M., Stevens,
D. M., Davis, J. G., Salmon, A. B.,
Richardson,A.,Ahima,R. S.,Guertin,
D. A., Sabatini, D. M., and Baur, J. A.
(2012). Rapamycin-induced insulin
resistance is mediated by mTORC2
loss and uncoupled from longevity.
Science 335, 1638–1643.
Larsen, J. L., Bennett, R. G., Burkman,
T., Ramirez, A. L., Yamamoto, S.,
Gulizia, J., Radio, S., and Hamel, F.
G. (2006). Tacrolimus and sirolimus
cause insulin resistance in normal
sprague dawley rats. Transplantation
82, 466–470.
Larsson, N. G., Wang, J., Wilhelmsson,
H., Oldfors, A., Rustin, P., Lewan-
doski, M., Barsh, G. S., and Clayton,
D. A. (1998). Mitochondrial tran-
scription factor A is necessary for
mtDNA maintenance and embryo-
genesis in mice. Nat. Genet. 18,
231–236.
Lashinger, L. M., Malone, L. M., Brown,
G. W., Daniels, E. A., Goldberg, J. A.,
Otto, G., Fischer, S. M., and Hurst-
ing, S. D. (2011). Rapamycin partially
mimics the anticancer effects of calo-
rie restriction in a murine model of
pancreatic cancer. Cancer Prev. Res.
(Phila) 4, 1041–1051.
Liu, Q., Kirubakaran, S., Hur, W., Nie-
pel, M., Westover, K., Thoreen, C.
C., Wang, J., Ni, J., Patricelli, M. P.,
Vogel, K., Riddle, S., Waller, D. L.,
Traynor, R., Sanda, T., Zhao, Z., Kang,
S. A., Zhao, J., Look, A. T., Sorger,
P. K., Sabatini, D. M., and Gray, N.
S. (2012). Kinome-wide selectivity
proﬁling of ATP-competitive mam-
malian target of rapamycin (mTOR)
inhibitors and characterization of
their binding kinetics. J. Biol. Chem.
287, 9742–9752.
McKee Alderman, J., DePetrillo, M.
A., Gluesenkamp, A. M., Hartley, A.
C., Verhoff, S. V., Zavodni, K. L.,
and Combs, T. P. (2010). Calorie
restriction and dwarf mice in geron-
tological research. Gerontology 56,
404–409.
Menzies, R. A., and Gold, P. H. (1971).
The turnover of mitochondria in a
variety of tissues of young adult and
aged rats. J. Biol. Chem. 246, 2425–
2429.
Miller, R. A., Harrison, D. E., Astle,
C., Baur, J. A., de Cabo, R., Fer-
nandez, E., Flurkey, K., Javors, M.,
Nelson, J., Pletcher, S., Sharp, Z.,
Sinclair, D. A., Starnes, J., Wilkin-
son, J., Nadon, N., and Strong, R.
(2010). Rapamycin, but not resver-
atrol or simvastatin, extends lifespan
of genetically heterogeneous mice. J.
Gerontol. A Biol. Sci. Med. Sci. 66,
191–201.
Morino, K., Petersen, K. F., and
Shulman, G. I. (2006). Molecular
mechanisms of insulin resistance in
humans and their potential links with
mitochondrial dysfunction. Diabetes
Metab. Res. Rev. 55(Suppl. 2),
S9 –S15.
Nisoli, E., Tonello, C., Cardile, A., Cozzi,
V., Bracale, R., Tedesco, L., Falcone,
S., Valerio, A., Cantoni, O., Clementi,
E., Moncada, S., and Carruba, M. O.
(2005). Calorie restriction promotes
mitochondrial biogenesis by induc-
ing the expression of eNOS. Science
310, 314–317.
Noguchi, N., Yoshikawa, T., Ikeda,
T., Takahashi, I., Shervani, N. J.,
Uruno, A., Yamauchi, A., Nata,
K., Takasawa, S., Okamoto, H.,
and Sugawara, A. (2008). FKBP12.6
disruption impairs glucose-induced
insulin secretion. Biochem. Biophys.
Res. Commun. 371, 735–740.
Ojuka, E.O. (2004). Role of calciumand
AMPkinase in the regulationof mito-
chondrial biogenesis and GLUT4 lev-
els in muscle. Proc. Nutr. Soc. 63,
275–278.
Pearson, K. J., Baur, J. A., Lewis, K.
N., Peshkin, L., Price, N. L., Labin-
skyy, N., Swindell, W. R., Kamara, D.,
Minor, R. K., Perez, E., Jamieson, H.
A., Zhang,Y.,Dunn, S. R., Sharma,K.,
Pleshko, N., Woollett, L. A., Csiszar,
A., Ikeno, Y., Le Couteur, D., Elliott,
P. J., Becker, K. G., Navas, P., Ingram,
D. K., Wolf, N. S., Ungvari, Z., Sin-
clair, D. A., and de Cabo, R. (2008).
Resveratrol delays age-related deteri-
oration and mimics transcriptional
aspects of dietary restriction without
extending life span. Cell Metab. 8,
157–168.
Ramanathan, A., and Schreiber, S. L.
(2009). Direct control of mitochon-
drial function by mTOR. Proc. Natl.
Acad. Sci. U.S.A. 106, 22229–22232.
Sabatini, D. M., Erdjument-Bromage,
H., Lui, M., Tempst, P., and Snyder,
S. H. (1994). RAFT1: a mammalian
protein that binds to FKBP12 in a
rapamycin-dependent fashion and is
homologous to yeast TORs. Cell 78,
35–43.
Sarbassov, D. D., Ali, S. M., Sengupta, S.,
Sheen, J. H., Hsu, P. P., Bagley, A. F.,
Markhard, A. L., and Sabatini, D. M.
(2006). Prolonged rapamycin treat-
ment inhibitsmTORC2 assembly and
Akt/PKB. Mol. Cell. 22, 159–168.
Sarbassov, D. D., Guertin, D. A., Ali,
S. M., and Sabatini, D. M. (2005).
Phosphorylation and regulation of
Akt/PKB by the rictor-mTOR com-
plex. Science 307, 1098–1101.
Schieke, S. M., Phillips, D., McCoy, J.
P., Jr., Aponte, A. M., Shen, R. F.,
Balaban, R. S., and Finkel, T. (2006).
The mammalian target of rapamycin
(mTOR) pathway regulates mito-
chondrial oxygen consumption and
oxidative capacity. J. Biol. Chem. 281,
27643–27652.
Selman, C., Tullet, J. M., Wieser, D.,
Irvine, E., Lingard, S. J., Choud-
hury, A. I., Claret, M., Al-Qassab,
H., Carmignac, D., Ramadani, F.,
Woods, A., Robinson, I. C., Schus-
ter, E., Batterham, R. L., Kozma, S. C.,
Thomas, G., Carling, D., Okkenhaug,
K., Thornton, J. M., Partridge, L.,
Gems, D., and Withers, D. J. (2009).
Ribosomal protein S6 kinase 1 signal-
ing regulates mammalian life span.
Science 326, 140–144.
Shinmura, K., Tamaki, K., Sano, M.,
Murata, M., Yamakawa, H., Ishida,
H., and Fukuda, K. (2011). Impact
of long-term caloric restriction on
cardiac senescence: caloric restriction
ameliorates cardiac diastolic dysfunc-
tion associatedwith aging. J.Mol. Cell
Cardiol. 50, 117–127.
Smith, D. L. Jr., Elam, C. F. Jr., Mat-
tison, J. A., Lane, M. A., Roth, G.
S., Ingram, D. K., and Allison, D. B.
(2010). Metformin supplementation
and life span in Fischer-344 rats. J.
Gerontol. A Biol. Sci. Med. Sci. 65,
468–474.
www.frontiersin.org September 2012 | Volume 3 | Article 177 | 9
“fgene-03-00177” — 2012/9/10 — 17:44 — page 10 — #10
Ye et al. Rapamycin disrupts mTORC2 in myotubes
Stallone, G., Infante, B., Grandaliano,
G., and Gesualdo, L. (2009). Man-
agement of side effects of sirolimus
therapy. Transplantation 87, S23–S26.
Teutonico, A., Schena, P. F., and Di
Paolo, S. (2005). Glucose metabolism
in renal transplant recipients: effect
of calcineurin inhibitor withdrawal
and conversion to sirolimus. J. Am.
Soc. Nephrol. 16, 3128–3135.
Thoreen, C. C., Kang, S. A., Chang,
J. W., Liu, Q., Zhang, J., Gao,
Y., Reichling, L. J., Sim, T., Saba-
tini, D. M., and Gray, N. S.
(2009). An ATP-competitive mam-
malian target of rapamycin inhibitor
reveals rapamycin-resistant functions
of mTORC1. J. Biol. Chem. 284,
8023–8032.
Um, S. H., Frigerio, F., Watanabe, M.,
Picard, F., Joaquin, M., Sticker, M.,
Fumagalli, S., Allegrini, P. R., Kozma,
S. C., Auwerx, J., and Thomas, G.
(2004). Absence of S6K1 protects
against age- and diet-induced obesity
while enhancing insulin sensitivity.
Nature 431, 200–205.
Weindruch, R., and Walford, R. L.
(1988). The Retardation of Aging
and Disease by Dietary Restriction,
Vol. xvii. Springﬁeld, IL: Charles C.
Thomas, 436.
Wu, Z., Puigserver, P., Andersson, U.,
Zhang, C., Adelmant, G., Mootha,
V., Troy, A., Cinti, S., Lowell, B.,
Scarpulla, R. C., and Spiegelman,
B. M. (1999). Mechanisms control-
ling mitochondrial biogenesis and
respiration through the thermogenic
coactivator PGC-1. Cell 98, 115–124.
Xin, H. B., Senbonmatsu, T., Cheng, D.
S., Wang, Y. X., Copello, J. A., Ji, G. J.,
Collier,M. L., Deng, K. Y., Jeyakumar,
L. H., Magnuson, M. A., Inagami,
T., Kotlikoff, M. I., and Fleischer, S.
(2002). Oestrogen protects FKBP12.6
null mice from cardiac hypertrophy.
Nature 416, 334–338.
Zhang, J. (2006). Resveratrol inhibits
insulin responses in a SirT1-
independent pathway. Biochem.
J. 397, 519–527.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 21 June 2012; accepted: 23
August 2012; published online: 11
September 2012.
Citation: Ye L, Varamini B, Lam-
ming DW, Sabatini DM and Baur
JA (2012) Rapamycin has a biphasic
effect on insulin sensitivity in C2C12
myotubes due to sequential disruption
of mTORC1 and mTORC2. Front.
Gene. 3:177. doi: 10.3389/fgene.2012.
00177
This article was submitted to Frontiers in
Genetics of Aging, a specialty of Frontiers
in Genetics.
Copyright © 2012 Ye, Varamini, Lam-
ming, Sabatini andBaur. This is an open-
access article distributed under the terms
of the Creative Commons Attribution
License, which permits use, distribution
and reproduction in other forums, pro-
vided the original authors and source
are credited and subject to any copy-
right notices concerning any third-party
graphics etc.
Frontiers in Genetics | Genetics of Aging September 2012 | Volume 3 | Article 177 | 10
